组蛋白脱乙酰基酶
化学
药理学
计算生物学
组蛋白
癌症研究
医学
生物
生物化学
DNA
作者
Romain Pacaud,Jose Garcia,Scott Thomas,Pamela N. Munster
出处
期刊:Elsevier eBooks
[Elsevier]
日期:2023-01-01
卷期号:: 793-819
标识
DOI:10.1016/b978-0-323-91909-8.00002-5
摘要
Aberrations in histone acetyltransferases (HATs) and histone deacetylases (HDACs) have been associated with tumor development and tumor progression. Pharmacological interference with histone acetylation and methylation has shown to be promising for the treatment and prevention of cancer, however, its optimal application remains under investigation. Several structurally and functionally different HDAC inhibitors (HDACi) have been developed to reverse aberrant epigenetic changes in cancer cells. With a growing body of literature, there is ample preclinical rationale to test these drugs in various stages and settings of cancer, either as single agents or in rationally designed combinations as a therapeutic strategy in hematological as well as solid tumor malignancies. The first HDACi vorinostat (Zolinza) was approved for the treatment of patients with cutaneous T-cell lymphoma. HDACi have also demonstrated great promise in treating a variety of noncancer diseases, including epilepsy, cystic fibrosis, spinal muscular atrophy, and human immunodeficiency virus infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI